Illumina, Inc. (ILMN)
Corvex's Meister joins the board at Illumina. Here's how he can create value for shareholders
Keith Meister, Corvex Management's chief investment officer, will join Illumina's board starting March 28. He's no stranger to the world of biotech.
Is Illumina Undervalued After An 83% Drop In Its Stock Price?
The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing market is expected to grow by 14.90%-21.65% CAGR in the following ten years.
Activist investor Keith Meister to join Illumina's board, WSJ reports
Activist investor Keith Meister will join the board of gene-sequencing maker Illumina , and current board member Scott Gottlieb will become chairman, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.
Activist Investor Meister to Join Illumina's Board
Keith Meister's hedge fund Corvex Management has a 2.5% stake in the gene-sequencing machine maker.
Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain?
ILMN-NashBio's AGD initiative achieves the milestone of completing 250,000 whole genomes.
Why Illumina (ILMN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Illumina lowers outlook due to China sales ban, to cut $100 million in costs
Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban on imports of its genetic sequencing instruments.
Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban
Beijing banned imports of Illumina's gene-sequencing machines in response to U.S. tariffs.
Illumina Stock Drops as China Bans Imports of Gene-Sequencing Technology
Illumina was placed on China's list of ‘unreliable entities' in February.
China bans imports of Illumina's gene sequencers
China announced a ban on Tuesday on imports of genetic sequencers from U.S. medical equipment maker Illumina , just minutes after U.S. President Donald Trump's additional 10% tariff on Chinese goods took effect.
Here's Why Illumina (ILMN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Illumina, Inc. (ILMN) AGBT Investor Session Conference (Transcript)
Illumina, Inc. (NASDAQ:ILMN ) AGBT Investor Session Conference February 25, 2025 11:00 AM ET Company Participants Salli Schwartz - Head of Investor Relations Jacob Thaysen - Chief Executive Officer Steve Barnard - Chief Technology Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Dan Arias - Stifel Puneet Souda - SVB Securities Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies LLC Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Kyle Mikson - Canaccord Genuity Salli Schwartz Welcome. Thank you for your patience while we got started.
